Drug Type Bispecific killer cell engager (BiKE) |
Synonyms |
Target |
Action antagonists, inhibitors |
Mechanism CD16a antagonists(Low affinity immunoglobulin gamma Fc region receptor III-A antagonists), CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Hodgkin Lymphoma | Preclinical | - | - |






